Loading...
Please wait, while we are loading the content...
Similar Documents
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
| Content Provider | Scilit |
|---|---|
| Author | Tam, Constantine S. Quach, Hang Nicol, Andrew Badoux, Xavier Rose, Hannah Prince, H. Miles Leahy, Michael F. Eek, Richard Wickham, Nicholas Patil, Sushrut S. Huang, Jane Prathikanti, Radha Cohen, Aileen Elstrom, Rebecca Reed, William Schneider, Jingjing Flinn, Ian W. |
| Copyright Year | 2020 |
| Description | Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducted a phase 1 study to assess the safety of its combination with obinutuzumab and evaluate early efficacy in 81 patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or relapsed/refractory (R/R) follicular lymphoma (FL). In this phase 1b study, zanubrutinib was tolerable at 160 mg twice daily or 320 mg once daily combined with IV obinutuzumab in patients with CLL/SLL (n = 45) and FL (n = 36). Common adverse events (AEs) included upper respiratory tract infection (51%; n = 23), neutropenia (44%; n = 20), contusion (33%; n = 15), cough, diarrhea, or fatigue (27%; n = 12 each), and pyrexia (22%; n = 10) in CLL/SLL patients and upper respiratory tract infection (39%; n = 14), contusion (28%; n = 10), fatigue (25%; n = 9), and cough (22%; n = 8) in FL patients. Neutropenia was the most common grade 3/4 AE (CLL/SLL, 31% [n = 14]; FL, 14% [n = 5]). Five patients required temporary dose reductions, and 5 discontinued the study drug because of AEs. Overall response rate (ORR) was 100% (n = 20) in treatment-naïve CLL patients and 92% (n = 23) in R/R CLL patients. ORR in 36 R/R FL patients was 72% (n = 26), with 14 complete and 12 partial responses. Median follow-up was 29 months (range, 8-37) for CLL patients and 20 months (range, 2-37) for FL patients. Zanubrutinib and obinutuzumab combination therapy was generally well tolerated. This trial was registered at www.clinicaltrials.gov as #NCT02569476. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556127/pdf |
| Ending Page | 4811 |
| Page Count | 10 |
| Starting Page | 4802 |
| DOI | 10.1182/bloodadvances.2020002183 |
| Journal | Blood advances |
| Issue Number | 19 |
| Volume Number | 4 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2020-10-13 |
| Access Restriction | Open |
| Subject Keyword | Hematology Efficacy Fatigue Respiratory Neutropenia Cll Orr Contusion Obinutuzumab Tolerated Bgb Journal: Blood advances (Vol- 129, Issue- 19) |
| Content Type | Text |
| Resource Type | Article |
